Incyte lining up pemigatinib filing on ESMO data

With updated data presented at ESMO, Incyte said it will submit an NDA to FDA this year to seek accelerated approval of its FGFR inhibitor in a niche cancer indication of cholangiocarcinoma. The biotech also has plans to expand the pemigatinib program to include a tissue-agnostic

Read the full 463 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE